Clinical trial design limitations in head and neck squamous cell carcinomas

Current Opinion in Oncology

Volumn 19, Issue 3, 2007, Pages 210-215

  Yun, Hwan Jung ^a   Bogaerts, Jan ^a   Awada, Ahmad ^b   Lacombe, Denis ^a  

^a EORTC DATA CENTER   (Belgium)

^b JULES BORDET INSTITUTE   (Belgium)

Author keywords

Head and neck cancer; Methodological interpretation; Randomized trials

Indexed keywords

AMIFOSTINE; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; GEFITINIB;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL STUDY; CLINICAL TRIAL; HEAD AND NECK CARCINOMA; HUMAN; HYPOPHARYNX CANCER; LARYNX CARCINOMA; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; PHARYNX CARCINOMA; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; SQUAMOUS CELL CARCINOMA; TREATMENT FAILURE; XEROSTOMIA;

AMIFOSTINE; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; RADIATION-PROTECTIVE AGENTS; RANDOMIZED CONTROLLED TRIALS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS;

EID: 34247128295     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3280d2b8d7     Document Type: Review

References (60)

1. International Agency for Research on Cancer. GLOBOCAN 2002. CANCERMondial. http://www-dep.iarc.fr [accessed 30 January 2007].
2. Al-Sarraf M, Hussein M. Head and neck cancer: present status and future prospects of adjuvant chemotherapy. Cancer Invest 1995; 13:41-53.
3. Leon X, Quer M, Orus C, et al. Can cure be achieved in patients with head and neck carcinomas? The problem of second neoplasm. Expert Rev Anticancer Ther 2001; 1:125-133.
4. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991; 324:1685-1690.
5. Lefebvre JL, Chevalier D, Luboinski B, et al. Larynx preservation in pyriform sinus cancer: Preliminary results of a European Organization for Research and Treatment of Cancer Phase III trial - EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996; 88:890-899.
6. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349:2091-2098.
7. Calais G, Pointreau Y, Alfonsi M, et al. Randomized phase III trial comparing induction chemotherapy using cisplatin (P) fluorouracil (F) with or without docetaxel (T) for organ preservation in hypopharynx and larynx cancer. Preliminary results of GORTEC 2000-01 [abstract]. J Clin Oncol 2006; 24 (18S):5506.
8. Lewin F, Damber L, Jonsson H, et al. Neoadjuvant chemotherapy with cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the head and neck: a randomized phase III study. Radiother Oncol 1997; 43:23-28.
9. Domenge C, Hill C, Lefebvre JL, et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tete et du Cou (GETTEC). Br J Cancer 2000; 83:1594-1598.
10. Licitra L, Grandi C, Guzzo M, et al. Primary chemotherapy in resectable oral cavity squamous cell cancer: A randomized controlled trial. J Clin Oncol 2003; 15:327-333.
11. Zorat PL, Paccagnella A, Cavaniglia G, et al. Randomised phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. J Natl Cancer Inst 2004; 96:1714-1717.
12. Forastiere AA. Randomized trials of induction chemotherapy: A critical review. Hematol Oncol Clin North Am 1991; 5:725-736.
13. Paccagnella A, Orlando A, Marchiori C, et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: A study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 1994; 86:265-272.
14. Schuller DE, Metch B, Stein DW, et al. Preoperative chemotherapy in advanced resectable head and neck cancer: Final report of the Southwest Oncology Group. Laryngoscope 1988; 98:1205-1211.
15. Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: Three meta-analyses of updated individual data - MACH-NC Collaborative Group: Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000; 355:949-955.
16. Remenar E, Van Herpen C, Germa Lluch J, et al. A randomised phase III multicenter trial of neoadjuvant docetaxel plus cisplatin and 5-fluorouracil (TPF) versus neoadjuvant PF in patients with locally advanced unresectable squamous cell carcinoma of the head and neck (SCCHN). Final analysis of EORTC 24971 [abstract]. J Clin Oncol 2006; 24 (18S):5516.
17. Hitt R, López-Pousa A, Martínez-Trufero J, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005; 1:8636-8645.
18. Hitt R, Grau J, Lopez-Pousa A, et al. Randomised phase II/III clinical trial of induction chemotherapy (ICT) with either cisplatin/5- fluorouracil (PF) or docetaxel/cisplatin/5-fluorouracil (TPF) followed by chemoradiotherapy (CRT) vs. CRT alone for patients (pts) with unresectable locally advanced head and neck cancer (LAHNC) [abstract]. J Clin Oncol 2006; 24 (18S): 5515.
19. Posner MR, Hershock D, Le Lann L, et al. TAX 324: A phase III trial of TPF vs. PF induction chemotherapy followed by chemoradiotherapy in locally advanced SCCHN [abstract]. In Proceedings of the 2006 ASCO Annual Meeting, 2-6 June 2006, Atlanta, GA: http://www.asco.org/portal/site/ ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid= 76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_ detail_view& confID=40&abstractID=90001 [accessed 5 February 2007].
20. Adelstein DJ, Saxton JP, Lavertu P, et al. Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer with hyperfractionated radiation and concurrent chemotherapy. J Clin Oncol 2002; 20:1405-1410.
21. Machtay M, Rosenthal DI, Hershock D, et al. Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma: A University of Pennsylvania phase II trial. J Clin Oncol 2002; 20:3964-3971.
22. Kies MS, Haraf DJ, Rosen F, et al. Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. J Clin Oncol 2001; 19:1961-1969.
23. Sanchiz F, Milla A, Torner J, et al. Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys 1990; 19:1347-1350.
24. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998; 338:1798-1804.
25. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999; 91:2081-2086.
26. Jeremic B, Shibamoto Y, Milicic B, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: A prospective randomized trial. J Clin Oncol 2000; 18:1458-1464.
27. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004; 22:69-76.
28. Merlano M, Benasso M, Corvo R, et al. Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst 1996; 88:583-589.
29. Wendt TG, Grabenbauer GG, Rodel CM, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: A randomized multicenter study. J Clin Oncol 1998; 16:1318-1324.
30. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003; 21:92-98.
31. Fountzilas G, Ciuleanu E, Dafni U, et al. Concomitant radiochemotherapy vs. radiotherapy alone in patients with head and neck cancer. A Hellenic Cooperative Oncology Group phase III study. Med Oncol 2004; 21:95-107.
32. Haraf DJ, Rosen FR, Stenson K, et al. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin Cancer Res 2003; 9:5936-5943.
33. Vokes EE, Kies M, Haraf DJ, et al. Induction chemotherapy followed by concomitant chemoradiotherapy for advanced head and neck cancer: Impact on the natural history of the disease. J Clin Oncol 1995; 13:876-883.
34. Hainsworth JD, Meluch AA, McClurkan S, et al. Induction paclitaxel, carboplatin, and infusional FU followed by concurrent radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally advanced head and neck cancer: A phase II trial of the Minnie Pearl Cancer Research Network. Cancer J 2002; 8:311-321.
35. Vokes EE, Stenson K, Rosen FR, et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: Curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol 2003; 21:320-326.
36. Paccagnella A, Buffoli A, Koussis H, et al. Randomized phase II trial of concomitant CT/RT versus TPF followed by concomitant CT/RT in locally advanced squamous cell carcinoma of the head and neck (LASCCHN) [abstract]. J Clin Oncol 2006; 24 (18S):5518.
37. Bachaud JM, Cohen-Jonathan E, Alzieu C, et al. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: Final report of a randomized trial. Int J Radiat Oncol Biol Phys 1996; 36:999-1004.
38. Laramore GE, Scott CB, al-Sarraf M, et al. Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: Report on Intergroup Study 0034. Int J Radiat Oncol Biol Phys 1992; 23:705-713.
39. Bernier J, Domenge C, Ozsahin M, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous cell carcinoma of the head and neck. N Engl J Med 2004; 350:1945-1952.
40. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiochemotherapy for high-risk squamous cell carcinoma of the head and neck. N Engl J Med 2004; 350:1937-1944.
41. Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC(#22931) and RTOG(#9501). Head & Neck 2005; 27:843-850.
42. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23:5578-5587.
43. Baselga J, Trigo J, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23:5568-5577.
44. Trigo J, Hitt R, Koralewski P, et al. Cetuximab monotherapy is active in patients with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck: results of a phase II study [abstract]. J Clin Oncol 2004; 22 (Suppl):488.
45. Vermorken JB, Bourhis J, Trigo J, et al. Cetuximab (Erbitux1) in recurrent/metastatic (R&M) squamous cell carcinoma of the head and neck (SCCHN) refractory to first-line platinum-based therapies [abstract]. J Clin Oncol 2005; 23 (16S):5505.
46. Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005; 23:8646-8654.
47. Bourhis J, Rivera F, Mesia R, et al. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J ClinOncol 2006; 24:2866-2872. The article evaluates the activity of cetuximab in combination with platinum-based combination chemotherapy as a first-line treatment in recurrent/metastatic disease.
48. Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003; 21:1980-1987.
49. Wheeler RH, Jones D, Sharma P, et al. Clinical and molecular phase II study of gefitinib in patients (pts) with recurrent squamous cell cancer of the head and neck (H&N Ca) [abstract]. J Clin Oncol 2005; 23 (16S):5531.
50. Cohen EE, Kane MA, List MA, et al. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Clin Cancer Res 2005; 11:8418-8424.
51. Belón J, Irigoyen A, Rodríguez I, et al. Preliminary results of a phase II study to evaluate gefitinib combined with docetaxel and cisplatin in patients with recurrent and/or metastatic squamous-cell carcinoma of the head and neck [abstract]. J Clin Oncol 2005; 23 (16S):5563.
52. Cohen EE, Haraf DJ, Stenson KM, et al. Integration of Gefitinib (G), into a concurrent chemoradiation (CRT) regimen followed by G adjuvant therapy in patients with locally advanced head and neck cancer (HNC) - a phase II trial [abstract]. J Clin Oncol 2005; 23 (16S):5506.
53. Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22:77-85.
54. Kim ES, Kies M, Sabichi A, et al. Phase II study of combination cisplatin, docetaxel and erlotinib in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC) [abstract]. J Clin Oncol 2005; 23 (16S):5546.
55. Vokes EE, Cohen EE, Mauer AM, et al. A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC) [abstract]. J Clin Oncol 2005; 23 (16S):5504.
56. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-578. An important trial showing cetuximab can add efficacy to radiotherapy without any additional side effects. This treatment can be an appropriate option for patients who cannot receive platinum-based therapy.
57. Pfister DG, Su YB, Kraus DH, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced squamous cell head and neck cancer: A pilot phase II study of a new combined-modality paradigm. J Clin Oncol 2006; 24:1072-1078.
58. Sasse AD, Clark LGO, Sasse EC, et al. Amifostine reduces side effects and improves complete response rate during radiotherapy: Results of a meta-analysis. Int J Radiat Oncol Biol Phys 2006; 64:784-791. This analysis defined the role of amifostine in preventing the side effects of radiotherapy.
59. Antonadou D, Pepelassi M, Synodinou M, et al. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head and neck cancer. Int J Radiat Oncol Biol Phys 2002; 52:739-747.
60. Buentzel J, Micke O, Adamietz IA, et al. Intravenous amifostine during chemoradiotherapy for head and neck cancer: A randomized placebo-controlled phase III study. Int J Radiat Oncol Biol Phys 2006; 64:684-691. The article explores the role of amifostine in preventing side effects of concomitant chemoradiation in the treatment of head and neck cancer.